Day: January 8, 2026

Orbit International Reports Consolidated Bookings for Month of December 2025 of Approximately $3,400,000

Written by Customer Service on January 8, 2026. Posted in Public Companies.

Fourth Quarter Bookings Approximately $6,200,000 HAUPPAUGE, N.Y., Jan. 08, 2026 (GLOBE NEWSWIRE) — Orbit International Corp. (the “Company”) (OTCID Basic Market:ORBT), an electronics manufacturer and software solution provider, today announced that consolidated bookings for the month of December 2025 were approximately $3,400,000. This firm month of bookings for December helped push consolidated bookings for the fourth quarter of 2025 to approximately $6,200,000. The bookings for the month of December 2025 were primarily due to strong bookings recorded by both its Orbit Instrument division, part of its Orbit Electronics Group (“OEG”) and its Orbit Power Group (“OPG”). Deliveries for orders received during the month have already commenced and are expected to continue through the second quarter of 2027. Mitchell Binder, President...

Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones

Written by Customer Service on January 8, 2026. Posted in Public Companies.

Database locks for studies on actinic keratosis (AK) and acne vulgaris achieved on January 5, 2026 Data generated will support key regulatory milestones for Ameluz PDT in both indications AK and acne are the two most commonly diagnosed skin disorders in the US1WOBURN, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the successful database lock of two clinical studies evaluating Ameluz® PDT, marking an important milestone ahead of several anticipated data and regulatory events in 2026. The databases for the treatment phase of the Company’s Phase 3 clinical study evaluating Ameluz® PDT for the treatment of actinic keratosis (AK) on the extremities,...

Telos Corporation Renews $5.4M Cyber GRC Engagement with Leading Global Technology Company

Written by Customer Service on January 8, 2026. Posted in Public Companies.

Contract expansion reflects nearly four-year relationship supporting large-scale cloud security and compliance operations ASHBURN, Va., Jan. 08, 2026 (GLOBE NEWSWIRE) — Telos Corporation (NASDAQ: TLS), a leading provider of cyber, cloud and enterprise security solutions for the world’s most security-conscious organizations, today announced the renewal of its ongoing partnership with a Fortune 100 global technology company to deliver cyber governance, risk, and compliance (GRC) and security operations support for large-scale commercial cloud environments. The agreement, valued at $5.4 million, reflects the continued growth of a relationship that began in July 2022. In support of the customer, Telos will continue providing cyber GRC oversight across multiple cloud product lines, supporting the maintenance of existing authorities...

Alpha Modus Advances AlphaCash Rollout, Highlighting Scalable Path to Embedded Financial Access in Grocery and Convenience Retail

Written by Customer Service on January 8, 2026. Posted in Public Companies.

Follow‑On Update Builds on Recently Announced National Retail Pilot and Enterprise Deployment PartnershipAlpha Modus Advances AlphaCash Retail Financial Services Kiosk RolloutAlpha Modus’ AlphaCash financial services kiosk deployed in a grocery retail environment, illustrating the company’s scalable approach to embedded financial access for underbanked consumers.CORNELIUS, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) — Building on its recently announced national retail pilot and enterprise deployment partnership, Alpha Modus Holdings, Inc. (NASDAQ: AMOD) is providing additional context around the AlphaCash kiosk platform, outlining how embedded financial services inside grocery and convenience retail environments can scale efficiently while expanding access for underbanked consumers. Together, these developments reflect more...

PCI Biotech announces discontinuation of R&D operations and continues evaluation of future options

Written by Customer Service on January 8, 2026. Posted in Public Companies.

Oslo (Norway), 8 January 2026 – PCI Biotech (OSE: PCIB). Reference is made to the company’s latest announcement dated 23rd October 2025. The external evaluation of a new bioprocessing technology has been concluded, with no prospects for further collaboration. As PCI Biotech’s limited operations were contingent upon sustained external interest, all R&D operations will now be discontinued. In recent months, various strategic alternatives have been explored, and this process continues. The evaluation is made with careful consideration of the company’s circumstances, and includes a range of options, including, but not limited to, a merger or a structured wind-up of the company. The liquidity position of the PCI Biotech group remains critical, and there is no assurance that additional financing can be secured. These material uncertainties...

CorMedix Therapeutics Announces Leadership and Board Updates

Written by Customer Service on January 8, 2026. Posted in Public Companies.

BERKELEY HEIGHTS, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) — CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced an addition to its executive leadership team and updates to its Board of Directors. CorMedix CEO Joseph Todisco has signed an extended employment contract, reaffirming his long-term commitment to the organization. In addition to his role as CEO, Mr. Todisco will also assume the role of Chairman of the Board of Directors, succeeding Myron Kaplan. Mr. Kaplan will transition into a newly created board position of Lead Independent Director. “Under the leadership of Mr. Todisco, CorMedix has evolved from a single product, development stage company into a multi-product, diversified commercial...

MannKind Provides Business Updates and 2026 Growth Drivers

Written by Customer Service on January 8, 2026. Posted in Public Companies.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today provided business updates and outlined anticipated growth drivers for 2026, including progress across its commercial programs and clinical development initiatives. “MannKind closed 2025 on a high note, marked by milestones that reinforce our growth trajectory—including the acquisition of scPharmaceuticals and a record-setting fourth quarter surpassing $100 million in net revenue,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. “With two high-potential launches on the horizon, 2026 is shaping up to be a catalyst-rich...

Colabor Group Inc. Files Application for Creditor Protection Under the CCAA

Written by Customer Service on January 8, 2026. Posted in Public Companies.

SAINT-BRUNO-DE-MONTARVILLE, Quebec, Jan. 08, 2026 (GLOBE NEWSWIRE) — Colabor Group Inc. (TSX: GCL) (“Colabor” or the “Company”), announces that the Company and certain of its subsidiaries, Transport Paul-Émile Dubé Ltée, Le Groupe Resto-Achats Inc. and Norref Fisheries Quebec Inc., will apply today to the Superior Court of Quebec (Commercial Division) (the “Court”) for an initial order to seek protection from their creditors under the Companies’ Creditors Arrangement Act (“CCAA”). In its application for an initial order, the Company seeks the approval of a formal sale and investment solicitation process (“SISP”) in order to provide interested parties with the opportunity to submit proposals with a view to determine the best possible transaction for the Company, its concerned subsidiaries and its stakeholders....

AXIL Brands, Inc. Reports Second Quarter Fiscal Year 2026 Financial Results

Written by Customer Service on January 8, 2026. Posted in Earnings Releases And Operating Results.

LOS ANGELES, Jan. 08, 2026 (GLOBE NEWSWIRE) — AXIL Brands, Inc. (“AXIL,” “we,” “us,” “our,” or the “Company”) (NYSE American: AXIL), an emerging global consumer products company for AXIL® hearing protection and enhancement products and Reviv3® hair and skin care products, today announced financial and operational results for the second quarter ended November 30, 2025 (2Q26). Financial Highlights (Quarter Ended November 30, 2025)Net sales increased to $8.1 million, compared to $7.7 million in the prior year period, an increase of 5.2% Gross profit of $5.5 million, or 68.1% of sales, compared to $5.5 million, or 71.1% in the prior year period Operating expenses declined to $4.6 million, or 57.0% of net sales compared to $4.8 million, or 62.4% of net sales in the prior year period Net income increased to $704,833, compared to $633,706...

Northern Technologies International Corporation Reports Financial Results for First Quarter Fiscal 2026

Written by Customer Service on January 8, 2026. Posted in Earnings Releases And Operating Results.

MINNEAPOLIS, Jan. 08, 2026 (GLOBE NEWSWIRE) — Northern Technologies International Corporation (NASDAQ: NTIC), a leading developer of corrosion inhibiting products and services, as well as bio-based and biodegradable polymer resin compounds, today reported its financial results for the first quarter of fiscal 2026. First quarter fiscal 2026 financial and operating highlights include (with growth rates on a fiscal quarter year-over-year basis):Consolidated net sales increased 9.2% to a quarterly record of $23,309,000 ZERUST® industrial net sales increased 6.9% to a quarterly record of $14,923,000 ZERUST® oil and gas net sales increased 58.1% to a first quarter record of $2,394,000 Natur-Tec® product net sales increased 2.2% to a quarterly record of $5,993,000 NTIC China net sales increased 23.5% to a quarterly record of $4,935,000 Gross...

M	T	W	T	F	S	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Day: January 8, 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals